cefalexin 500mg tablets
kent pharma (uk) ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
sun pharma uk ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
alliance healthcare (distribution) ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
arrow generics ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
pliva pharma ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
dowelhurst ltd - cefalexin - oral tablet - 500mg
cefalexin 500mg tablets
phoenix healthcare distribution ltd - cefalexin - oral tablet - 500mg
cefalexin sandoz
sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg; - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg excipient: gelatin magnesium stearate microcrystalline cellulose titanium dioxide water
cefalexin 500mg tablets
flynn pharma ltd - cefalexin - oral tablet - 500mg
cefalexin (flynn)
max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml; - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.